化合物信息

ID:777

基本信息

化学结构

分子式

C₂₈H₃₁NO₅

分子量

461.54944

精确质量

461.2202231

电荷

InChI

InChI=1S/C28H31NO5/c1-18-6-10-20(11-7-18)26(31)33-24-15-14-22(23(30)17-29-28(3,4)5)16-25(24)34-27(32)21-12-8-19(2)9-13-21/h6-16,23,29-30H,17H2,1-5H3

InChIKey

FZGVEKPRDOIXJY-UHFFFAOYSA-N

Canonic Smiles

Cc1ccc(cc1)C(=O)Oc1cc(ccc1OC(=O)c1ccc(cc1)C)C(CNC(C)(C)C)O

Isomeric Smiles

OC(CNC(C)(C)C)c1cc(OC(=O)c2ccc(cc2)C)c(OC(=O)c2ccc(cc2)C)cc1

计算属性

JChem

LogD (pH = 7.4)

4.15

LogD (pH = 5.5)

3.12

Log P

6.30

可自由旋转的化学键

质子供体

质子受体

里宾斯基五规则

false

Acid pKa

9.59

极化表面积

84.86

极化性

50.86

摩尔折射率

132.76

LOG S

-6.83

数据来源

学术数据

数据来源

名称和标识

IUPAC标准名

5-[2-(tert-butylamino)-1-hydroxyethyl]-2-(4-methylbenzoyloxy)phenyl 4-methylbenzoate 4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(4-methylbenzoyloxy)phenyl 4-methylbenzoate

商标名

Tornalate

别名

BitolterolBitolterol MesylateBitolterolum [INN-Latin]bis(4-methylbenzoic acid) 4-[2-(tert-butylamino)-1-hydroxyethyl]-1,2-phenylene ester4-(2-(tert-butylamino)-1-hydroxyethyl)-o-phenylene di-p-toluate4-[2-(tert-butylamino)-1-hydroxyethyl]-o-phenylene di-p-toluatebitolterol

IUPAC传统名

5-[2-(tert-butylamino)-1-hydroxyethyl]-2-(4-methylbenzoyloxy)phenyl 4-methylbenzoate bitolterol

国际非专利药品(INN)

bitolterolbitolterolum

名称和标识

数据登录号

PubChem CID

35330

PubChem SID

1609642404650689592740965

CAS号

KEGG ID

ACToR数据库

CHEBI ID

专利号

Beilstein号

PubMed文献链接

CompTox数据库

MetaboLights数据库

Drug Central Database

Reaxys Registry

SureChEMBL数据库

DrugBank ID

KEGG DRUG Database

CHEMBL

维基百科标题

数据登录号

化合物性质

理化性质

疏水性(logP)

5.8

化合物性质

分子相关蛋白质

暂无数据

点击上传数据

分子相关蛋白质

分子图谱

暂无数据

点击上传数据

描述信息

DrugBank

DB00901

Drug Groups

withdrawn

Description

Bitolterol mesylate is a beta-2-adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and COPD. Bitolterol was withdrawn from the market by Elan Pharmaceuticals in 2001. [Wikipedia]

Indication

Used to dilate air passages in the lungs that have become narrowed as a result of disease or inflammation. It is used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).

Pharmacology

Bitolterol, an adrenergic bronchodilator, is a prodrug that widens constricted airways in the lungs by relaxing the smooth muscles that surround the bronchial passages. Bitolterol probably does not affect the inflammation in the lung, such as in bronchitis. Bitolterol is unique in that it is a prodrug because it must first be metabolized by the body before it becomes active.

Affected Organisms

Humans and other mammals

References

• Bierman CW, Kemp JP, Nathan RA: Efficacy and safety of inhaled bitolterol mesylate via metered-dose inhaler in children with asthma. Ann Allergy Asthma Immunol. 1996 Jan;76(1):27-35. [Pubmed]

• Friedel HA, Brogden RN: Bitolterol. A preliminary review of its pharmacological properties and therapeutic efficacy in reversible obstructive airways disease. Drugs. 1988 Jan;35(1):22-41. [Pubmed]

• Nathan RA, Bronsky EA, Dockhorn RJ, Kemp JP: Multicenter dose-ranging study of bitolterol mesylate solution for nebulization in children with asthma. Ann Allergy. 1994 Mar;72(3):209-16. [Pubmed]

• Messina MS: Retrospective study of bitolterol mesylate in the treatment of conditions associated with reversible bronchospasm. Adv Ther. 1995 May-Jun;12(3):157-63. [Pubmed]

External Links

• [Wikipedia]

• [Drugs.com]

描述信息

参考文献

PubChem文献

数据源提供

• Bierman CW, Kemp JP, Nathan RA: Efficacy and safety of inhaled bitolterol mesylate via metered-dose inhaler in children with asthma. Ann Allergy Asthma Immunol. 1996 Jan;76(1):27-35. Pubmed

• Messina MS: Retrospective study of bitolterol mesylate in the treatment of conditions associated with reversible bronchospasm. Adv Ther. 1995 May-Jun;12(3):157-63. Pubmed

• Friedel HA, Brogden RN: Bitolterol. A preliminary review of its pharmacological properties and therapeutic efficacy in reversible obstructive airways disease. Drugs. 1988 Jan;35(1):22-41. Pubmed

• Nathan RA, Bronsky EA, Dockhorn RJ, Kemp JP: Multicenter dose-ranging study of bitolterol mesylate solution for nebulization in children with asthma. Ann Allergy. 1994 Mar;72(3):209-16. Pubmed

参考文献

生物活性

PubChem BioAssay

生物活性

导航

基本信息

计算属性

• RDKit

• JChem

数据来源

• 学术数据

名称和标识

• IUPAC标准名

• 商标名

• 别名

• IUPAC传统名

• 国际非专利药品(INN)

名称和标识

数据登录号

• PubChem CID

• PubChem SID

• CAS号

• KEGG ID

• ACToR数据库

• CHEBI ID

• 专利号

• Beilstein号

• PubMed文献链接

• CompTox数据库

• MetaboLights数据库

• Drug Central Database

• Reaxys Registry

• SureChEMBL数据库

• DrugBank ID

• KEGG DRUG Database

• CHEMBL

• 维基百科标题

• 理化性质

• DrugBank

• ChEBI

描述信息

参考文献

• PubChem文献

• 数据源提供

生物活性

• PubChem BioAssay

IUPAC标准名

5-[2-(tert-butylamino)-1-hydroxyethyl]-2-(4-methylbenzoyloxy)phenyl 4-methylbenzoate 4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(4-methylbenzoyloxy)phenyl 4-methylbenzoate

别名

IUPAC传统名

5-[2-(tert-butylamino)-1-hydroxyethyl]-2-(4-methylbenzoyloxy)phenyl 4-methylbenzoate bitolterol

国际非专利药品(INN)

bitolterolbitolterolum

理化性质

疏水性(logP)

5.8

数据源提供

• Bierman CW, Kemp JP, Nathan RA: Efficacy and safety of inhaled bitolterol mesylate via metered-dose inhaler in children with asthma. Ann Allergy Asthma Immunol. 1996 Jan;76(1):27-35. Pubmed

• Messina MS: Retrospective study of bitolterol mesylate in the treatment of conditions associated with reversible bronchospasm. Adv Ther. 1995 May-Jun;12(3):157-63. Pubmed

• Friedel HA, Brogden RN: Bitolterol. A preliminary review of its pharmacological properties and therapeutic efficacy in reversible obstructive airways disease. Drugs. 1988 Jan;35(1):22-41. Pubmed

• Nathan RA, Bronsky EA, Dockhorn RJ, Kemp JP: Multicenter dose-ranging study of bitolterol mesylate solution for nebulization in children with asthma. Ann Allergy. 1994 Mar;72(3):209-16. Pubmed

ACToR数据库

Beilstein号

PubMed文献链接

CompTox数据库

MetaboLights数据库

Drug Central Database

Reaxys Registry

SureChEMBL数据库

KEGG DRUG Database

维基百科标题

暂无数据

点击上传数据

DrugBank

DB00901

Drug Groups

withdrawn

Description

Indication

Used to dilate air passages in the lungs that have become narrowed as a result of disease or inflammation. It is used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).

Pharmacology

Affected Organisms

Humans and other mammals

References

• Bierman CW, Kemp JP, Nathan RA: Efficacy and safety of inhaled bitolterol mesylate via metered-dose inhaler in children with asthma. Ann Allergy Asthma Immunol. 1996 Jan;76(1):27-35. [Pubmed]

• Nathan RA, Bronsky EA, Dockhorn RJ, Kemp JP: Multicenter dose-ranging study of bitolterol mesylate solution for nebulization in children with asthma. Ann Allergy. 1994 Mar;72(3):209-16. [Pubmed]

• Messina MS: Retrospective study of bitolterol mesylate in the treatment of conditions associated with reversible bronchospasm. Adv Ther. 1995 May-Jun;12(3):157-63. [Pubmed]

External Links

• [Wikipedia]

• [Drugs.com]

ChEBI

CHEBI:3133

The di-4-toluate ester of (+-)-N-tert-butylnoradrenaline (colterol). A pro-drug for colterol, a beta2-adrenergic receptor agonist, bitolterol is used as its methanesulfonate salt for relief of bronchospasm in conditions such as asthma, chronic bronchitis and emphysema.